REVOLUTION MEDICINES INC. - COMMON STOCK

Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress

06 ноя 2023 13:05:18 Источник Nasdaq GlobeNewswire

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Revolution Medicines Stockholders Vote “FOR” Proposed Acquisition of EQRx, Inc.

01 ноя 2023 04:00:00 Источник Nasdaq GlobeNewswire

Revolution Medicines to Report Financial Results for Third Quarter 2023 After Market Close on November 6, 2023

31 окт 2023 13:15:00 Источник Nasdaq GlobeNewswire

Revolution Medicines Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236

21 окт 2023 23:30:28 Источник Nasdaq GlobeNewswire

Revolution Medicines Presents Encouraging Clinical Data for RMC-6236 and RMC-6291 at 2023 Triple Meeting

13 окт 2023 08:50:29 Источник Nasdaq GlobeNewswire

Revolution Medicines to Present New Clinical Data at Major Oncology Conferences and Host Investor Webcast

04 окт 2023 13:05:07 Источник Nasdaq GlobeNewswire

Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor

19 сен 2023 04:00:38 Источник Nasdaq GlobeNewswire

Revolution Medicines Announces Publication Describing Molecular Basis of Tri-Complex Inhibitors Targeting Oncogenic RAS(ON) Proteins

17 авг 2023 13:05:58 Источник Nasdaq GlobeNewswire

Revolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate Progress

08 авг 2023 13:05:04 Источник Nasdaq GlobeNewswire

Revolution Medicines to Report Financial Results for Second Quarter 2023 After Market Close on August 8, 2023

03 авг 2023 13:05:54 Источник Nasdaq GlobeNewswire

Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital

01 авг 2023 04:00:00 Источник Nasdaq GlobeNewswire

Revolution Medicines to Participate in Upcoming Investor Conferences

08 июн 2023 13:05:17 Источник Nasdaq GlobeNewswire

Revolution Medicines to Participate in TD Cowen 4th Annual Oncology Innovation Summit

24 май 2023 13:05:00 Источник Nasdaq GlobeNewswire

Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress

08 май 2023 13:02:00 Источник Nasdaq GlobeNewswire

Revolution Medicines to Report Financial Results for First Quarter 2023 After Market Close on May 8, 2023

01 май 2023 13:05:37 Источник Nasdaq GlobeNewswire

Revolution Medicines to Participate in 22nd Annual Needham Healthcare Conference

13 апр 2023 13:05:40 Источник Nasdaq GlobeNewswire

Revolution Medicines to Present Preclinical Data at the Upcoming American Association for Cancer Research Annual Meeting 2023

06 апр 2023 04:00:54 Источник Nasdaq GlobeNewswire

Revolution Medicines Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

07 мар 2023 13:02:17 Источник Nasdaq GlobeNewswire

Revolution Medicines Announces Pricing of $300.0 Million Public Offering of Common Stock

02 мар 2023 18:15:55 Источник Nasdaq GlobeNewswire

Revolution Medicines Announces Commencement of Public Offering of Common Stock

01 мар 2023 13:17:35 Источник Nasdaq GlobeNewswire